-
Role of LRRK2 in Levodopa-induced Dyskinesia
… Study Design: We will examine the role of LRRK2 in dyskinesia, a debilitating abnormal movement which is a common complication of PD treatment, by first creating dyskinesia with standard medications in pre-clinical models …
-
Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia
… brain systems. In this project we intend to counteract dyskinesia and worsening of motor function by co-targeting … or the NMDA receptor antagonist Amantadine to counteract dyskinesia and worsening of the therapeutic effect of L-DOPA …
-
Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease
… Inhibition for the Treatment of Levodopa-induced Dyskinesia Study Rationale: Neurosteroids are substances … 5 alpha reductase (5AR) dampens involuntary movement, or dyskinesia, in models of Parkinson’s that only affects one …
-
Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability
… efficacy and side effects (uncontrolled movements called dyskinesia) are caused by activating dopamine D1 receptors. … pathways downstream of D1 receptors for efficacy without dyskinesia. Using Sinopia’s machine learning platform, we …
-
Eltoprazine for Treatment of Levodopa-induced Dyskinesias
… in the brain — for alleviation of involuntary movements, dyskinesias, in Parkinson's disease (PD) patients, who can …
-
mTORC1 as a Target for the Treatment of Levodopa-induced Dyskinesia
… : The choreic and dystonic movements, or dyskinesia, which develop in response to prolonged treatment … for PD. Using a pre-clinical model of levodopa-induced dyskinesia (LID), we found that this condition is associated …